Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir

Autor: Brent D. Weinberg, Rafi Ahmed, Alvaro Perez Daisson, Soumon Rudra, Troy Kleber, Jeffrey M. Switchenko, Clayton B. Hess, Tony Y. Eng, Tahseen H. Nasti, Mohammad K. Khan, Vishal R. Dhere, Nadine Rouphael, Sibo Tian, Luisa S. Taverna
Rok vydání: 2021
Předmět:
medicine.medical_specialty
medicine.medical_treatment
TTCR
time to clinical recovery
Gastroenterology
Dexamethasone
law.invention
OS
overall survival
PCR
polymerase chain reaction
Pharmacotherapy
Randomized controlled trial
law
Internal medicine
medicine
Intubation
Humans
Radiology
Nuclear Medicine and imaging
Prospective Studies
Lung
biology
business.industry
SARS-CoV-2
ARDS
Acute Respiratory Distress Syndrome
Hematology
P
F ratio: ratio of arterial pressure (mmHg) of oxygen (PaO2) to fraction of inspired oxygen (FiO2) [P:F ratio]
medicine.disease
CXR
chest x-ray
COVID-19 Drug Treatment
Clinical trial
Oxygen
Pneumonia
LD-RT
low-dose radiation therapy
Treatment Outcome
Oncology
Cohort
CRP
C-reactive protein
biology.protein
Original Article
Creatine kinase
business
CT
chest tomography
medicine.drug
Zdroj: Radiotherapy and Oncology
ISSN: 1879-0887
Popis: BACKGROUND: Low-dose radiotherapy (LD-RT) has produced anti-inflammatory effects in both animal models and early human trials of COVID-19-related pneumonia. The role of whole-lung LD-RT within existing treatment paradigms merits further study. METHODS: A phase II prospective trial studied the addition of LD-RT to standard drug treatments. Hospitalized and oxygen-dependent patients receiving dexamethasone and/or remdesevir were treated with 1.5 Gy whole-lung LD-RT and compared to a blindly-matched contemporaneous control cohort. RESULTS: Of 40 patients evaluated, 20 received drug therapy combined with whole-lung LD-RT and 20 without LD-RT. Intubation rates were 14% with LD-RT compared to 32% without (p = 0.09). Intubation-free survival was 77% vs. 68% (p = 0.17). Biomarkers of inflammation (C-reactive protein, p = 0.02) and cardiac injury (creatine kinase, p
Databáze: OpenAIRE
Externí odkaz: